{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"MCS Week 12","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.448","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"MCS Week 12","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.058","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"MCS Week 24","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.446","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"MCS Week 24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.401","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"PCS Week 12","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.001","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"PCS Week 12","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.001","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"PCS Week 24","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.001","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"PCS Week 24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.001","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.7","value":"1.6"},{"groupId":"OG001","spread":"9.7","value":"3.4"},{"groupId":"OG002","spread":"10.0","value":"2.4"}]}],"title":"Week 12 MCS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.8","value":"2.5"},{"groupId":"OG001","spread":"11.5","value":"3.2"},{"groupId":"OG002","spread":"10.6","value":"3.3"}]}],"title":"Week 24 MCS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.0","value":"3.3"},{"groupId":"OG001","spread":"8.8","value":"6.3"},{"groupId":"OG002","spread":"8.8","value":"6.4"}]}],"title":"Week 12 PCS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.2","value":"2.4"},{"groupId":"OG001","spread":"8.9","value":"6.4"},{"groupId":"OG002","spread":"9.3","value":"7.0"}]}],"title":"Week 24 PCS"}],"denoms":[{"counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"168"},{"groupId":"OG002","value":"174"}],"units":"Participants"}],"description":"The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \\[MCS\\] and physical \\[PCS\\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"MEAN","populationDescription":"mITT population includes all randomized participants who received at least 1 dose of the study drug. Participants were analyzed according to the study drug to which they were randomized. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using NRI.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12, Week 24","title":"Change From Baseline in Mental Component Score (MCS), Physical Component Score (PCS) of the Medical Outcomes Study 36-Item Short Form Health Survey Version 2 Acute (SF-36v2 Acute)","type":"SECONDARY","unitOfMeasure":"Units on a Scale"}